The antiproliferative effect of RU486 in normal or neoplastic cells appears to be complex; its action was found to be dependent on the interaction with progesterone receptor in cultured human meningioma cells (35) or with glucocorticoid receptor, in prostate cancer cells (13). Here, PGR is linked to prostate cancer.